

Organic & Biomolecular Chemistry

Accepted Manuscript



This article can be cited before page numbers have been issued, to do this please use: W. Mai, F. Wang, X. Zhang, S. Wang, Q. Duan and K. Lu, *Org. Biomol. Chem.*, 2018, DOI: 10.1039/C8OB01389F.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [author guidelines](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the ethical guidelines, outlined in our [author and reviewer resource centre](#), still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

PAPER

Nickel-Catalysed Radical Tandem Cyclisation/Arylation:
Practical Synthesis of 4-Benzyl-3,3-Difluoro- γ -Lactams

Cite this: DOI: 10.1039/x0xx00000x

Wen-Peng Mai,^{a*} Fei Wang,^a Xiao-Feng Zhang,^a Shi-Min Wang,^a Qun-Peng Duan,^a
and Kui Lu^{a,b*}Received 00th January 2012,
Accepted 00th January 2012


DOI: 10.1039/x0xx00000x

www.rsc.org/

Enabled by nickel catalysis, a practical access to synthesis of 4-benzyl-3,3-difluoro- γ -lactams has been developed via radical tandem cyclisation/arylation. This method features nickel catalyst, high reaction efficiency, good substrate tolerance and scope. This protocol proceeds through an intramolecular radical addition to form a primary alkyl radical followed by intermolecular Suzuki-type coupling.

Introduction

Fluorine-containing molecules are of particular interest in the fields of biomedicine, agriculture, and material sciences.¹ Thus, the development of novel and high efficient methods for the selective introduction of fluorinated moieties such as F, CF₂ and CF₃ into organic molecules has received much attention in the past few years.² Conceptually, introduction of a difluoromethylene group (CF₂) into some heterocycles could lead to the discovery of some interesting bioactive molecules.³ In addition, pyrrolidinone structures are also very important in many bioactive molecules.⁴ Pyrrolidinones containing difluoromethylene moiety may have more attractive properties in drug discovery.⁵ Consequently, it is a desirable task to explore new catalytic strategy to construct fluorinated pyrrolidinones. In 2012, Chen developed a synthesis of 3,3-difluoro- γ -lactam via radical addition of *N*-aryl halofluoroacetamide to alkyl substituted alkenes.⁶ Recently, highly efficient synthesis for 3,3-Difluoro- γ -lactams have been achieved in the presence of an iridium photocatalyst (Scheme 1a) or copper catalyst (Scheme 1b).⁷ Very recently, Wang et al also reported a Cu-catalysed aminodifluoroalkylation of alkenes for the synthesis of 3,3-Difluoro- γ -lactams which is similar with the work shown in Scheme 1b.⁸ However, the target of all the works is to develop the synthesis of 5-substituted-3,3-Difluoro- γ -lactams. As a part of our program of



Scheme 1 The synthesis of 3,3-difluoropyrrolidin-2-ones.

radical cyclisation and difluoroalkylation,⁹ herein, we describe the successful development of the Ni(II)-catalysed radical tandem cyclisation/arylation for the synthesis of 4-substituted-3,3-difluoro- γ -lactams (Scheme 1c).


Up to now, Pd^{10b-c,e,f} and Ni-catalysed^{10d,g,j} difluoroalkylations and visible-light photoredox^{10h} reaction have emerged as a powerful tool for the construction of Ar–CF₂R bond efficiently. As inexpensive catalyst, nickel has proved to be very effective for cross-couplings, especially for Suzuki–Miyaura and Negishi reactions in the past 20 years.¹¹ In recent years, the scope of nickel-catalysed cross-coupling reactions has expanded far beyond simple bi-aryl synthesis and are rapidly growing,¹² in which, considerable efforts have been dedicated towards expanding the scope of coupling partners. Despite the advances, nickel-catalysed an efficient cascade reaction which involves alkenes by a radical pathway to the diverse molecules containing difluoromethylene group is highly attractive.

^aSchool of Materials and Chemical Engineering, Henan University of Engineering, Zhengzhou, 450006, China. E-mail: maiwp@yahoo.com.

^bSchool of Chemical Engineering and Food Science, Zhengzhou Institute of Technology, Zhengzhou, 450044, China. E-mail: luckyliu@haue.edu.cn; Tel: +86-371-67718909

† Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/c000000x/

Results and discussion

Table 1 Optimization of reaction conditions^a


R = H, **1a**
 R = COOEt, **1e**

2a

[Ni]/ligand
 base, 80 °C
 dioxane, 8h

3aa or 3ea

L1, R = H
 L2, R = OMe
 L3, R = *t*-Bu

L4


additive:
 A1
 A2

Entry	[Ni] (mol %)	Ligand (mol %)	Base (eq)	Yield ^b (%)
1	Ni(NO ₃) ₂ •6H ₂ O (5)	L1(5)	K ₂ CO ₃ (3)	33
2	Ni(NO ₃) ₂ •6H ₂ O (5)	L2(5)	K ₂ CO ₃ (3)	51
3	Ni(NO ₃) ₂ •6H ₂ O (5)	L3(5)	K ₂ CO ₃ (3)	55(0) ^c
4	Ni(NO ₃) ₂ •6H ₂ O (5)	L4(5)	K ₂ CO ₃ (3)	trace
5	NiCl ₂ •DME (5)	L2(5)	K ₂ CO ₃ (3)	32
6	NiCl ₂ •DME (5)	L3(5)	K ₂ CO ₃ (3)	36
7	NiCl ₂ •DME (5)	L3(5)/A1(5)	K ₂ CO ₃ (3)	40(16) ^c
8	NiCl ₂ •DME (5)	L3(5)/A2(5)	K ₂ CO ₃ (3)	32
9	Ni(acac) ₃ (5)	L3(5)	K ₂ CO ₃ (3)	0
10	Ni(OAc) ₂ •4H ₂ O (5)	L3(5)	K ₂ CO ₃ (3)	0
11	Ni(OTf) ₂ (5)	L3(5)	K ₂ CO ₃ (3)	68(37) ^c
12	Ni(OTf) ₂ (5)	L3(5)/PPh ₃ (5)	K ₂ CO ₃ (3)	79(56) ^c
13	Ni(OTf) ₂ (5)	L3(5)/PPh ₃ (10)	K ₂ CO ₃ (3)	83
14	Ni(OTf) ₂ (7.5)	L3(7.5)/PPh ₃ (15)	K ₂ CO ₃ (3)	88
15 ^d	Ni(OTf) ₂ (7.5)	L3(7.5)/PPh ₃ (15)	K ₂ CO ₃ (3)	92(77) ^c
16 ^{d,e}	Ni(OTf) ₂ (7.5)	L3(7.5)/PPh ₃ (15)	K ₂ CO ₃ (3)	27

^aReaction conditions: **1a** or **1e** (0.75 mmol, 1.5 equiv), **2a** (0.5 mmol), Ni catalyst (5–7.5 mol%), Ligand (5–15 mol %), 1,4-dioxane (3.0 mL), under N₂ atmosphere, 80 °C, 8 h. ^b Isolated yield. ^c The yield in bracket is product **3ea**'s. ^d **1a** or **1e** (1.0 mmol), **2a** (0.5 mmol). ^e Under air.

Initially, we set out to examine the feasibility of the radical cascade process using *N*-allyl-2-bromo-2,2-difluoro-*N*-(4-methoxyphenyl)acetamide (**2a**) and phenylboronic acid (**1a**) as substrates. Selected optimization results are summarized in Table 1 (see Table S1 in SI). We first examined low-cost Ni(NO₃)₂•6H₂O as catalyst by using K₂CO₃ as base (entries 1–4). Screening the ligands from **L1** to **L4**, the best result was obtained when **L3** was chosen as ligand (Table 1, entry 3). However, it failed to furnish any of the desired product when electron-poor 3-(ethoxycarbonyl)-phenylboronic acid (**1e**) and **2a** were put in the cascade process under the same condition (entry 3). Thus, the central challenge was to improve Ni's catalytic performance in the use of less reactive arylboronic acids. When NiCl₂•DME was selected as catalyst, the similar results were obtained even if some additives (**A1** or **A2**) were used (entries 5–8). Other nickel complexes such as Ni(acac)₃ and

Ni(OAc)₂ were found to be not effective (entries 9–10). However, when the Ni(OTf)₂ was tested, it showed higher catalytic efficiency, giving products **3aa** and **3ea** in 68% and 37% isolated yields respectively (entry 11). To our delight, significant improvements were achieved when 5 mol% PPh₃ was added and the products **3aa** and **3ea** were obtained in 79% and 56% respectively (entry 12). The product yield could be increased to 88% when 7.5 mol %

Table 2 Scope of Arylboronic acids 1^{a,b}


1 + **2**

Ni(OTf)₂
 L3/PPh₃
 K₂CO₃, 80 °C, 8h
 1,4-dioxane

3

3aa, 92%
3ba, 70%
3ca, 89%
3da, 71%
3ea, 77%
3fa, 57%
3ga, 68%
3ha, 85%
3ia, 76%
3ja, 83%
3ka, 85%
3la, 81%
3ma, 75%
3na, 70%
3oa, 90%
3pb, 80% gram scale (1.31g)

unsuccessful boronic acids:
 N-B(OH)₂, B(OH)₂
 B(OH)₂

(X-ray)


^aReaction conditions: **1** (1.0 mmol), **2a** or **2b** (0.5 mmol), K₂CO₃ (3.0 equiv), Ni(OTf)₂ (7.5 mol %), **L3** (7.5 mol %) and PPh₃ (15 mol %) in 1,4-dioxane (3.0 mL) at 80 °C for 8 h. ^b Isolated yield.

Ni(OTf)₂ and 15 mol % PPh₃ were used as catalyst system (entry 14). Furthermore, excellent yield (92%) for **3aa** and good yield (77%) for **3ea** could be obtained when the ratio of **1a** (**1e**) to **2a** was 2:1 (entry 15).

With the optimized conditions in hand, we then investigated the scope of arylboronic acids in this reaction (Table 2). Arylboronic acids bearing various substituents, including electron-donating (**3c**, **3f**, **3m**, **3o**) and electron-withdrawing (**3b**, **3d–e**, **3g–i**) performed well in the cascade process. Compared with the electron-rich

arylboronic acids, those electron-poor analogues showed lower reactivity obviously. Many versatile functional groups, such as ketone, ester and sulphone were all tolerated under the reaction conditions (**3ba**, **3da**, **3ea** and **3ga**). Moreover, Boc-protected amine group was also compatible in this reaction, which provided possibility of further functionalization (**3fa**). Pleasingly, aromatic heterocyclic benzofuran-2-ylboronic acid could also perform well in this transformation and the desired product **3pb** was obtained in 80% yield even in gram-scale (5 mmol). The structure of product **3pb** was clearly confirmed by single crystal X-ray crystallographic analysis, which signified the cascade process was 5-*exo-trig* cyclisation (Table 2). It is noteworthy that alkyl boronic acid is not suitable for the current reaction. A possible reason is that it is more difficult for coordination and insertion with nickel catalyst. Furthermore arylboronic acids containing double bond and nitrogen are not compatible in this transformation (Table 2). Unfortunately, some *ortho*-substituted aryl boronic acids are not efficient coupling partners in this reaction (see details in ESI).


Subsequently, the scope of *N*-substituted groups in substrate **2** was evaluated and found to proceed smoothly in all the cases (Table 3). The nickel-catalysed cascade reaction between *N*-phenylacetamide **2b** and boronic acid **1a** proceeded efficiently to afford **3ab** in 92% yield. Good result was also obtained when **2b** reacted with **1k**, providing **3kb** in 80% yield (Table 3).

Table 3. Scope of Substrate 2.^a


When *N*-(3,5-dimethylphenyl)-acetamide **2c** was tested under the current conditions, excellent yield (94%) for **3ac** was achieved. Electron-withdrawing groups such as CF₃, F and acetyl on the *N*-substituted phenyl ring were well tolerated and have no influence on

product yield. In addition, no obvious changes were found when the substituents on *N*-substituted phenyl ring were electron-donating groups such as CH₃ and OMe, good yields were also obtained (**3ac**, **3af** and **3aj**). However, the transformation failed to furnish any of the desired products when the *N*-substituted groups were alkyl or allyl analogues (see Scheme S1 and S3 in ESI). The reason for this result is not clear at present.

In order to acquire further insight into the transformation mechanism, the standard reaction was performed in the presence of 1.5 equiv of TEMPO (2,2,6,6-tetramethyl-1-piperidinyloxy), a radical scavenger. To our surprise, the reaction did not proceed at all and the substrate **2a** was recovered in 55% yield (eq 1). The reason may be TEMPO deactivates the nickel catalyst at the beginning of the reaction. Addition of the ET scavenger 1,4-dinitrobenzene also shut down the reaction completely (eq 2). The above studies may support a SET pathway in the cascade process to a certain extent and suggest that a radical mechanism may be involved in the catalytic cycle. However, the substrate **2a** could not undergo the cyclisation and was recovered in 93% yield in the absence of phenylboronic acid which implied arylboronic acids play an important role in the transformation (eq 3). As shown in eq 3, it seems that only Ni catalyst does not initiate the reaction and arylboronic acid may play a role like activating agent.



Based on the above studies and previous works,¹⁰ a primary plausible mechanism for the nickel-catalysed tandem cyclisation-arylation is described in Scheme 2. Initially, the LNi(I)X complex **A** with **1** were translated into species **B**.^{10j} Then the Ni(I) complex **B** could initiate the generation of radical **D** from **2** through single electron transfer (SET), leading Ni(II) intermediate **C** in the meanwhile. The radical intermediate **D** forms radical **E** rapidly via 5-*exo-trig* cyclisation. After an oxidative radical addition, the **E** and **C** were transferred into Ni(III) complex **F**. Subsequently, **F** is transformed to the final product **3aa**, which undergoes reductive elimination of the nickel catalyst and regenerates species **A**.



Scheme 2 Proposed mechanism for the reaction

Conclusions

In summary, we have disclosed a high efficient synthesis of γ -lactams via inexpensive nickel-catalysed intramolecular radical cyclisation followed by intermolecular arylation of *N*-allyl-2-bromo-2,2-difluoro-*N*-arylacetyl amides with arylboronic acids, which provides a simple and straightforward route to various 4-benzyl-3,3-difluoropyrrolidin-2-ones. Further applications of this method to more wide substrates and the study of mechanism are ongoing in our laboratory.

Experimental section

General Procedure for the Radical Tandem Cyclisation-Arylation: The synthesis of 4-benzyl-3,3-difluoro-1-(4-methoxyphenyl)pyrrolidin-2-one (**3aa**). To a 25 mL of Schlenk tube were added phenylboronic acid **1a** (1.0 mmol, 0.122g, 2.0 equiv), **2a** (0.5 mmol, 0.16g), Ni(OTf)₂ (7.5 mmol %, 13 mg), DTBPy (7.5 mmol %, 10 mg), PPh₃ (15 mmol %, 19.6 mg) under air, followed by K₂CO₃ (1.5 mmol, 3.0 equiv). The mixture was then evacuated and backfilled with N₂ (3 times), dioxane (3 mL) were added subsequently. The tube was put into a preheated oil bath (80 °C). After stirring for 8 h, the reaction mixture was cooled to room temperature and was evaporated under reduced pressure. The residue was extracted with EtOAc (15 ml x 2) and then dried by Na₂SO₄. After removing EtOAc, the residue was purified with silica gel chromatography to give product **3aa** in 92% yield. White solid; ¹H NMR (400 MHz, CDCl₃) δ : 7.52 (d, *J* = 12.0 Hz, 2H), 7.30-7.36 (m, 2H), 7.26-7.30 (m, 3H), 6.93 (dd, *J* = 8.0, 4.0 Hz, 2H), 3.82 (s, 3H), 3.69 (t, *J* = 8.0 Hz, 1H), 3.60 (t, *J* = 8.0 Hz, 1H), 3.30 (dd, *J* = 16.0, 8.0 Hz, 1H), 2.95-2.99 (m, 1H), 2.79-2.85 (m, 1H); ¹³C NMR (100

MHz, CDCl₃) δ : 162.13 (t), 157.67, 136.96, 129.92, 128.97, 128.73, 127.10, 121.73, 114.95 (t, *J* = 257 Hz), 114.18, 55.48, 48.54, 41.67 (t, *J* = 21 Hz), 31.53; ¹⁹F NMR (376 MHz, CDCl₃) δ : -109.44 (d, *J* = 266.96 Hz), -117.03 (d, *J* = 266.96 Hz); HRMS (ESI) calcd for C₁₈H₁₈F₂NO₂ [M+H]⁺: 318.1300; found: 318.1308.

4-(3-acetylbenzyl)-3,3-difluoro-1-(4-methoxyphenyl)pyrrolidin-2-one(3ba) White solid; ¹H NMR (400 MHz, CDCl₃) δ : 7.88 (d, *J* = 8.0 Hz, 2H), 7.49 (d, *J* = 8.0 Hz, 4H), 6.92 (d, *J* = 8.0 Hz, 2H), 3.81 (s, 3H), 3.72 (t, *J* = 8.0 Hz, 1H), 3.59 (t, *J* = 8.0 Hz, 1H), 3.33 (dd, *J* = 12.0, 4.0 Hz, 1H), 2.97-3.02 (m, 1H), 2.88-2.94 (m, 1H), 2.63 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 197.90, 161.93 (t), 157.72, 137.72, 133.48, 129.27, 128.22, 127.37, 121.75, 117.35 (t, *J* = 247 Hz), 114.32, 55.49, 48.49, 41.30 (t, *J* = 21 Hz), 31.45, 26.71; ¹⁹F NMR (376 MHz, CDCl₃) δ : -109.13 (d, *J* = 266.96 Hz), -116.60 (d, *J* = 266.96 Hz); HRMS (ESI) calcd for C₂₀H₂₀F₂NO₃ [M+H]⁺: 360.1406; found: 360.1411.

4-(3,5-dimethoxybenzyl)-3,3-difluoro-1-(4-ethoxyphenyl)pyrrolidin-2-one(3ca) Pale yellow solid; ¹H NMR (400 MHz, CDCl₃) δ : 7.52 (d, *J* = 8.0 Hz, 2H), 6.93 (d, *J* = 8.0 Hz, 2H), 6.40 (s, 3H), 3.82 (s, 9H), 3.71 (t, *J* = 8.0 Hz, 1H), 3.57 (t, *J* = 8.0 Hz, 1H), 3.24 (dd, *J* = 16.0, 4.0 Hz, 1H), 2.91-2.96 (m, 1H), 2.70-2.77 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 161.79, 161.20, 157.67, 139.24, 130.97, 121.75, 117.37 (t, *J* = 244 Hz), 114.29, 106.81, 98.63, 55.50, 48.53, 41.51 (t, *J* = 21 Hz), 31.77; ¹⁹F NMR (376 MHz, CDCl₃) δ : -109.44 (d, *J* = 366.96 Hz), -116.97 (d, *J* = 366.96 Hz); HRMS (ESI) calcd for C₂₀H₂₂F₂NO₄ [M+H]⁺: 378.1511; found: 378.1514.

methyl-4-((4,4-difluoro-1-(4-methoxyphenyl)-5-oxopyrrolidin-3-yl)methyl)benzoate(3da) white solid; ¹H NMR (400 MHz, CDCl₃) δ : 8.05 (d, *J* = 8.0 Hz, 2.0Hz), 7.50 (d, *J* = 8.0 Hz, 2.0Hz), 7.36 (d, *J* = 8.0 Hz, 2.0Hz), 6.92 (d, *J* = 8.0 Hz, 2.0Hz), 3.94 (s, 3H), 3.81 (s, 3H), 3.72 (t, *J* = 8.0 Hz, 1H), 3.59 (t, *J* = 8.0 Hz, 1H), 3.34 (dd, *J* = 16.0, 4.0 Hz, 1H), 2.94-2.98 (m, 1H), 2.86-2.92 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 166.72, 161.89 (t), 157.72, 142.28, 130.85, 130.25, 129.18, 128.81, 121.69, 117.14 (t, *J* = 255 Hz), 114.32, 55.49, 52.18, 48.43 (d), 41.40 (t, *J* = 21 Hz), 31.57; ¹⁹F NMR (376 MHz, CDCl₃) δ : -109.24 (d, *J* = 266.96 Hz), -116.68 (d, *J* = 266.96 Hz); HRMS (ESI) calcd for C₂₀H₂₀F₂NO₄ [M+H]⁺: 376.1355, found: 376.1355.

ethyl-3-((4,4-difluoro-1-(4-methoxyphenyl)-5-oxopyrrolidin-3-yl)methyl)benzoate(3ea) white solid; ¹H NMR (400 MHz, CDCl₃) δ : 7.95-7.99 (m, 2H), 7.44-7.50 (m, 4H), 6.91 (d, *J* = 8.0 Hz), 4.43 (q, *J* = 8.0 Hz, 2H), 3.80 (s, 3H), 3.69 (t, *J* = 8.0 Hz, 1H), 3.59 (t, *J* = 8.0 Hz, 1H), 3.33 (dd, *J* = 16.0, 8.0 Hz, 1H), 2.94-3.00 (m, 1H), 2.86-2.92 (m, 1H), 1.42 (t, *J* = 8.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 166.31, 162.29 (t), 157.70, 137.32, 133.22, 130.88, 129.65, 129.04, 128.34, 121.75, 117.45 (t, *J* = 233 Hz), 114.30, 61.18, 55.48, 48.47 (d), 41.51 (t, *J* = 21 Hz), 31.33, 14.34; ¹⁹F NMR (376 MHz, CDCl₃) δ : -109.28 (d, *J* = 266.96 Hz), -116.67 (d, *J* = 266.96 Hz); HRMS (ESI) calcd for C₂₁H₂₂F₂NO₄ [M+H]⁺: 390.1511, found: 390.1515.

tert-butyl(4-((4,4-difluoro-1-(4-methoxyphenyl)-5-oxopyrrolidin-3-yl)methyl)phenyl)carbamate(3fa) white solid; ¹H NMR (400

MHz, CDCl₃) δ : 7.51 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 8.0 Hz, 2H), 6.92 (d, J = 8.0 Hz, 2H), 6.58 (s, 1H), 3.81 (s, 3H), 3.69 (t, J = 8.0 Hz, 1H), 3.56 (t, J = 8.0 Hz, 1H), 3.24 (dd, J = 12.0, 8.0 Hz, 1H), 2.85-2.93 (m, 1H), 2.72-2.78 (m, 1H), 1.54 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ : 162.16 (t), 157.64, 152.83, 137.42, 131.33, 130.98, 129.24, 121.69, 119.86, 117.55 (t, J = 231 Hz), 114.29, 80.64, 55.49, 48.49, 41.70 (t, J = 21 Hz), 30.82, 28.34; ¹⁹F NMR (376 MHz, CDCl₃) δ : -109.26 (d, J = 266.96 Hz), -116.99 (d, J = 266.96 Hz); HRMS (ESI) calcd for C₂₃H₂₇F₂N₂O₄ [M+H]⁺: 433.1933, found: 433.1930.

3,3-difluoro-1-(4-methoxyphenyl)-4-(4-

(methylsulfonyl)benzyl)pyrrolidin-2-one(3ga) Pale yellow solid; ¹H NMR (400 MHz, CDCl₃) δ : 7.95 (d, J = 8.0 Hz, 2H), 7.51 (d, J = 8.0 Hz, 4H), 6.93 (d, J = 8.0 Hz, 2H), 3.82 (s, 3H), 3.75 (t, J = 8.0 Hz, 1H), 3.58 (t, J = 8.0 Hz, 1H), 3.36 (dd, J = 12.0, 4.0 Hz, 1H), 3.08 (s, 3H), 2.93-3.00 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ : 161.69 (t), 157.79, 143.51, 139.53, 130.71, 129.81, 128.07, 121.71, 117.24 (t, J = 248 Hz), 114.36, 55.51, 48.38, 44.48, 41.26 (t, J = 21 Hz), 31.59; ¹⁹F NMR (376 MHz, CDCl₃) δ : -108.85 (d, J = 266.96 Hz), -116.31 (d, J = 266.96 Hz); HRMS (ESI) calcd for C₁₉H₂₀F₂NO₄S [M+H]⁺: 396.1076, found: 396.1080.

4-(4-(tert-butyl)benzyl)-3,3-difluoro-1-(4-methoxyphenyl)pyrrolidin-2-one(3ha) white solid; ¹H NMR (400 MHz, CDCl₃) δ : 7.52 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 8.0 Hz, 2H), 6.93 (d, J = 8.0 Hz, 2H), 3.82 (s, 3H), 3.72 (t, J = 8.0 Hz, 1H), 3.56 (t, J = 8.0 Hz, 1H), 3.28 (dd, J = 16.0, 12.0 Hz, 1H), 2.91-2.99 (m, 1H), 2.76-2.82 (m, 1H), 1.35 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ : 162.20 (t), 157.67, 150.03, 133.80, 131.04, 128.39, 125.86, 121.80, 117.60 (t, J = 235 Hz), 114.29, 55.49, 48.65, 41.46 (t, J = 21 Hz), 34.49, 31.35; ¹⁹F NMR (376 MHz, CDCl₃) δ : -109.31 (d, J = 266.96 Hz), -117.16 (d, J = 266.96 Hz); HRMS (ESI) calcd for C₂₂H₂₆F₂NO₂ [M+H]⁺: 374.1926; found: 374.1923.

3,3-difluoro-4-(4-fluorobenzyl)-1-(4-methoxyphenyl)pyrrolidin-2-one(3ia) white solid; ¹H NMR (400 MHz, CDCl₃) δ : 7.51 (d, J = 8.0 Hz, 2H), 7.22-7.23 (m, 2H), 7.05 (t, J = 8.0 Hz, 2H), 6.91-6.94 (m, 2H), 3.82 (s, 3H), 3.71 (t, J = 8.0 Hz, 1H), 3.56 (t, J = 8.0 Hz, 1H), 3.25 (dd, J = 12.0, 4.0 Hz, 1H), 2.87-2.95 (m, 1H), 2.78-2.84 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 163.14 (d, J = 244 Hz), 162.02 (t), 157.71, 132.64, 130.92, 130.19, 121.71, 117.40 (t, J = 243 Hz), 115.72, 114.32, 55.49, 48.47, 41.53 (t, J = 21 Hz), 30.80; ¹⁹F NMR (376 MHz, CDCl₃) δ : -109.14 (d, J = 266.96 Hz), -115.54, -116.90 (d, J = 266.96 Hz); HRMS (ESI) calcd for C₁₈H₁₇F₃NO₂ [M+H]⁺: 336.1206, found: 336.1211.

3,3-difluoro-1-(4-methoxyphenyl)-4-(3-methylbenzyl)pyrrolidin-2-one(3ja) pale white solid; ¹H NMR (400 MHz, CDCl₃) δ : 7.52 (d, J = 8.0 Hz, 2H), 7.24-7.28 (m, 1H), 7.05-7.10 (m, 3H), 6.94 (d, J = 12.0 Hz, 2H), 3.82 (s, 3H), 3.69 (t, J = 8.0 Hz, 1H), 3.57 (t, J = 8.0 Hz, 1H), 3.28 (dd, J = 16.0, 4.0 Hz, 1H), 2.91-2.98 (m, 1H), 2.74-2.80 (m, 1H), 2.38 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 162.19, 157.65, 138.68, 136.87, 131.01, 129.48, 128.84, 127.84, 125.70, 121.75, 117.48 (t, J = 242 Hz), 55.50, 48.59, 41.69 (t, J = 21 Hz), 31.42, 21.42; ¹⁹F NMR (376 MHz, CDCl₃) δ : -109.48 (d, J = 266.96

Hz), -117.07 (d, J = 266.96 Hz); HRMS (ESI) calcd for C₁₉H₂₀F₂NO₂ [M+H]⁺: 332.1457, found: 332.1460.

4-(4-chlorobenzyl)-3,3-difluoro-1-(4-methoxyphenyl)pyrrolidin-2-one(3ka) white solid; ¹H NMR (400 MHz, CDCl₃) δ : 7.51 (d, J = 8.0 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 6.94 (d, J = 8.0, 4.0 Hz, 2H), 3.82 (s, 3H), 3.73 (t, J = 8.0 Hz, 1H), 3.57 (t, J = 8.0 Hz, 1H), 3.27 (dd, J = 8.0, 4.0 Hz, 1H), 2.88-2.95 (m, 1H), 2.78-2.84 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 161.95 (t), 157.71, 135.39, 133.03, 130.87, 130.08, 129.13, 121.70, 119.87 (t, J = 269 Hz), 114.33, 55.51, 48.43, 41.58 (t, J = 21 Hz), 30.97; ¹⁹F NMR (376 MHz, CDCl₃) δ : -109.07 (d, J = 266.96 Hz), -116.78 (d, J = 266.96 Hz); HRMS (ESI) calcd for C₁₈H₁₇ClF₂NO₂ [M+H]⁺: 352.0910, found: 352.0915.

3,3-difluoro-4-(3-fluoro-4-methylbenzyl)-1-(4-methoxyphenyl)pyrrolidin-2-one(3la) white solid; ¹H NMR (400 MHz, CDCl₃) δ : 7.52 (d, J = 12 Hz, 2.0Hz), 7.17 (t, J = 8.0 Hz, 1H), 6.91-6.95 (m, 4H), 3.82 (s, 3H), 3.71 (t, J = 12 Hz, 1H), 3.58 (t, J = 12 Hz, 1H), 3.25 (dd, J = 12.0, 8.0 Hz, 1H), 2.87-2.93 (m, 1H), 2.75-2.81 (m, 1H), 2.28 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 162.63, 162.03 (t, J = 32 Hz), 160.19, 157.69, 136.5(d), 131.96, 130.93, 124.11, 123.51, 121.72, 117.26 (t, J = 252 Hz), 115.35(d), 114.31, 55.49, 48.47, 41.54 (t, J = 21 Hz), 30.97(d), 14.22(d); ¹⁹F NMR (376 MHz, CDCl₃) δ : -109.26 (d, J = 266.96 Hz), -116.74, -116.86 (d, J = 266.96 Hz); HRMS (ESI) calcd for C₁₉H₁₉F₃NO₂ [M+H]⁺: 350.1362, found: 350.1366.

3,3-difluoro-1-(4-methoxyphenyl)-4-(4-(trifluoromethyl)benzyl)pyrrolidin-2-one(3ma) white solid; ¹H NMR (400 MHz, CDCl₃) δ : 7.65 (d, J = 8.0 Hz, 2H), 7.51 (d, J = 8.0 Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 6.94 (d, J = 8.0 Hz, 2H), 3.82 (s, 3H), 3.73 (t, J = 8.0 Hz, 1H), 3.62 (t, J = 8.0 Hz, 1H), 3.34 (dd, J = 8.0, 4.0 Hz, 1H), 2.88-2.99 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ : 161.79 (t), 157.76, 141.07, 130.79, 129.13, 125.88 (d, J = 4.0 Hz), 121.72, 117.18 (t, J = 274 Hz), 114.35, 55.50, 48.41, 41.24 (t, J = 20 Hz), 31.47; ¹⁹F NMR (376 MHz, CDCl₃) δ : -62.53, -109.15 (d, J = 266.96 Hz), -116.66 (d, J = 266.96 Hz); HRMS (ESI) calcd for C₁₉H₁₇F₃NO₂ [M+H]⁺: 386.1174; found: 386.1172.

3,3-difluoro-1-(4-methoxyphenyl)-4-(naphthalen-2-ylmethyl)pyrrolidin-2-one(3na) white solid; ¹H NMR (400 MHz, CDCl₃) δ : 7.83-7.88 (m, 3H), 7.72 (s, 1H), 7.50-7.52 (m, 4H), 7.41 (d, J = 12 Hz, 1H), 6.92 (d, J = 12 Hz, 2H), 3.81 (s, 3H), 3.59-3.70 (m, 2H), 3.48 (dd, J = 12.0, 4.0 Hz, 1H), 3.06-3.11 (m, 1H), 2.98-3.04 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 162.13 (t), 157.65, 134.38, 133.55, 132.45, 130.98, 128.82, 127.75, 127.53, 127.37, 126.49, 125.97, 121.68, 117.31 (t, J = 214 Hz), 114.29, 55.49, 48.55, 41.59 (t, J = 21 Hz), 31.70; ¹⁹F NMR (376 MHz, CDCl₃) δ : -109.29 (d, J = 266.96 Hz), -116.82 (d, J = 266.96 Hz); HRMS (ESI) calcd for C₂₂H₂₀F₂NO₂ [M+H]⁺: 368.1457, found: 368.1455.

3,3-difluoro-4-(4-methoxybenzyl)-1-(4-methoxyphenyl)pyrrolidin-2-one(3oa) white solid; ¹H NMR (400 MHz, CDCl₃) δ : 7.52 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 8.0 Hz, 2H), 6.93 (t, J = 8.0 Hz, 2H), 3.82 (s, 3H), 3.69 (t, J = 8.0 Hz, 1H), 3.58 (t,

$J = 8.0$ Hz, 1H), 3.25 (dd, $J = 16.0, 8.0$ Hz, 1H), 2.85-2.94 (m, 1H), 2.73-2.79 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 162.19 (t), 158.65, 157.64, 131.02, 129.71, 128.82, 121.70, 121.61, 117.58 (t, $J = 244$ Hz), 114.34, 114.29, 55.50 (d, $J = 20$ Hz), 48.53, 41.85 (t, $J = 20$ Hz), 30.65; ^{19}F NMR (376 MHz, CDCl_3) δ : -109.25 (d, $J = 266.96$ Hz), -117.07 (d, $J = 266.96$ Hz); HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{20}\text{F}_2\text{NO}_3$ $[\text{M}+\text{H}]^+$: 348.1406, found: 348.1406.

4-(benzofuran-2-ylmethyl)-3,3-difluoro-1-phenylpyrrolidin-2-one(3pb)

pure crystal; ^1H NMR (400 MHz, CDCl_3) δ : 7.65 (d, $J = 8.0$ Hz, 2H), 7.57 (d, $J = 8.0$ Hz, 1H), 7.40-7.47 (m, 3H), 7.24-7.32 (m, 3H), 6.60 (s, 1H), 3.96 (t, $J = 8.0$ Hz, 1H), 3.76 (t, $J = 8.0$ Hz, 1H), 3.43 (dd, $J = 16.0, 4.0$ Hz, 1H), 3.15-3.22 (m, 1H), 3.05-3.11 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 162.02 (t), 154.96, 153.69, 137.80, 129.22, 128.33, 126.29, 124.14, 123.01, 120.76, 120.01, 117.17 (t, $J = 241$ Hz), 111.01, 104.54, 48.28 (d), 38.94 (t, $J = 21$ Hz), 24.89; ^{19}F NMR (376 MHz, CDCl_3) δ : -110.64 (d, $J = 266.96$ Hz), -118.80 (d, $J = 266.96$ Hz); HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{16}\text{F}_2\text{NO}_2$ $[\text{M}+\text{H}]^+$: 328.1144, found: 328.1141.

4-(4-chlorobenzyl)-3,3-difluoro-1-phenylpyrrolidin-2-one(3kb)

white solid; ^1H NMR (400 MHz, CDCl_3) δ : 7.62 (d, $J = 8.0$ Hz, 2H), 7.42 (t, $J = 8.0$ Hz, 2H), 7.36 (d, $J = 8.0$ Hz, 2H), 7.21-7.28 (m, 3H), 3.76 (t, $J = 8.0$ Hz, 1H), 3.59 (t, $J = 8.0$ Hz, 1H), 3.28 (dd, $J = 16.0, 8.0$ Hz, 1H), 2.89-2.97 (m, 1H), 2.79-2.85 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 162.25 (t), 137.81, 135.32, 133.07, 130.08, 129.21, 129.15, 126.26, 119.96, 117.18 (t, $J = 249$ Hz), 48.04, 41.32 (t, $J = 21$ Hz), 30.92; ^{19}F NMR (376 MHz, CDCl_3) δ : -109.17 (d, $J = 266.96$ Hz), -117.49 (d, $J = 266.96$ Hz); HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{15}\text{ClF}_2\text{NO}$ $[\text{M}+\text{H}]^+$: 322.0805, found: 322.0801.

4-benzyl-3,3-difluoro-1-phenylpyrrolidin-2-one(3ab)

pure crystal; ^1H NMR (400 MHz, CDCl_3) δ : 7.63 (d, $J = 8.0$ Hz, 2H), 7.33-7.41 (m, 4H), 7.23-7.29 (m, 4H), 3.74 (t, $J = 8.0$ Hz, 1H), 3.62 (t, $J = 8.0$ Hz, 1H), 3.32 (dd, $J = 12.0, 4.0$ Hz, 1H), 2.92-3.01 (m, 1H), 2.80-2.86 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 162.87 (t), 137.91, 136.89, 129.17, 129.01, 128.72, 127.15, 126.18, 119.99, 117.33 (t, $J = 21$ Hz), 48.16 (d), 41.65 (t, $J = 21$ Hz), 31.48 (d); ^{19}F NMR (376 MHz, CDCl_3) δ : -109.57 (d, $J = 266.96$ Hz), -117.24 (d, $J = 266.96$ Hz); HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{16}\text{F}_2\text{NO}$ $[\text{M}+\text{H}]^+$: 288.1194, found: 288.1192.

4-benzyl-1-(3,5-dimethylphenyl)-3,3-difluoropyrrolidin-2-one(3ac)

white solid; ^1H NMR (400 MHz, CDCl_3) δ : 7.41 (t, $J = 8.0$ Hz, 2H), 7.27-7.33 (m, 3H), 7.21 (s, 2H), 6.90 (s, 1H), 3.74 (t, $J = 8.0$ Hz, 1H), 3.61 (t, $J = 8.0$ Hz, 1H), 3.32 (dd, $J = 16.0, 8.0$ Hz, 1H), 2.90-3.00 (m, 1H), 2.79-2.85 (m, 1H), 2.34 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ : 162.68 (t), 138.93, 137.76, 136.98, 128.99, 128.74, 128.01, 127.10, 118.00, 117.42 (t, $J = 245$ Hz), 48.44, 41.68 (t, $J = 21$ Hz), 31.55, 21.43; ^{19}F NMR (376 MHz, CDCl_3) δ : -109.50 (d, $J = 266.96$ Hz), -117.29 (d, $J = 266.96$ Hz); HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{20}\text{F}_2\text{NO}$ $[\text{M}+\text{H}]^+$: 316.1507, found: 316.1504.

4-benzyl-3,3-difluoro-1-(4-fluorophenyl)pyrrolidin-2-one(3ad)

white solid; ^1H NMR (400 MHz, CDCl_3) δ : 7.60 (q, $J = 4.0$ Hz, 2H), 7.38 (t, $J = 8.0$ Hz, 2H), 7.27-7.31 (m, 3H), 7.12 (t, $J = 8.0$ Hz, 2H),

3.71 (t, $J = 8.0$ Hz, 1H), 3.60 (t, $J = 8.0$ Hz, 1H), 3.32 (dd, $J = 16.0, 8.0$ Hz, 1H), 2.91-3.04 (m, 1H), 2.80-2.86 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 162.36 (t), 161.6 (d, $J = 245$ Hz), 136.78, 133.97, 129.03, 128.72, 127.19, 121.90, 117.30 (t, $J = 249$ Hz), 116.09, 115.87, 48.40, 41.42 (t, $J = 21$ Hz), 31.44; ^{19}F NMR (376 MHz, CDCl_3) δ : -109.63 (d, $J = 266.96$ Hz), -115.10, -117.14 (d, $J = 266.96$ Hz); HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{15}\text{F}_3\text{NO}$ $[\text{M}+\text{H}]^+$: 306.1100, found: 306.1108.

4-benzyl-1-(4-chlorophenyl)-3,3-difluoropyrrolidin-2-one(3ae)

white solid; ^1H NMR (400 MHz, CDCl_3) δ : 7.65 (d, $J = 8.0$ Hz, 2H), 7.31-7.40 (m, 5H), 7.28 (d, $J = 8.0$ Hz, 2H), 3.71 (t, $J = 8.0$ Hz, 1H), 3.59 (t, $J = 8.0$ Hz, 1H), 3.32 (dd, $J = 16.0, 8.0$ Hz, 1H), 2.92-2.98 (m, 1H), 2.80-2.86 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 162.44 (t), 136.70, 136.45, 131.44, 129.23, 129.05, 128.71, 127.22, 117.13 (t, $J = 241$ Hz), 48.05 (d), 41.55 (t, $J = 21$ Hz), 31.42 (d); ^{19}F NMR (376 MHz, CDCl_3) δ : -111.20 (d, $J = 266.96$ Hz), -118.70 (d, $J = 266.96$ Hz); HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{15}\text{ClF}_2\text{NO}$ $[\text{M}+\text{H}]^+$: 322.0805, found: 322.0800.

4-benzyl-3,3-difluoro-1-(p-tolyl)pyrrolidin-2-one(3af)

white solid; ^1H NMR (400 MHz, CDCl_3) δ : 7.50 (d, $J = 8.0$ Hz, 2H), 7.40 (t, $J = 8.0$ Hz, 2H), 7.27-7.33 (m, 3H), 7.20 (d, $J = 8.0$ Hz, 2H), 3.74 (t, $J = 8.0$ Hz, 1H), 3.61 (t, $J = 8.0$ Hz, 1H), 3.32 (dd, $J = 16.0, 8.0$ Hz, 1H), 2.89-3.02 (m, 1H), 2.79-2.85 (m, 1H), 2.36 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ : 162.49 (t), 136.95, 136.07, 135.40, 129.68, 128.99, 128.73, 127.12, 119.98, 114.92 (t, $J = 252$ Hz), 48.26, 41.66 (t, $J = 21$ Hz), 31.52, 20.96; ^{19}F NMR (376 MHz, CDCl_3) δ : -111.00 (d, $J = 266.96$ Hz), -118.73 (d, $J = 266.96$ Hz); HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{18}\text{F}_2\text{NO}$ $[\text{M}+\text{H}]^+$: 302.1351, found: 302.1357.

4-benzyl-3,3-difluoro-1-(4-(trifluoromethyl)phenyl)pyrrolidin-2-one(3ag)

white solid; ^1H NMR (400 MHz, CDCl_3) δ : 7.78 (d, $J = 8.0$ Hz, 2H), 7.67 (d, $J = 8.0$ Hz, 2H), 7.39 (t, $J = 8.0$ Hz, 2H), 7.28-7.34 (m, 3H), 3.78 (t, $J = 8.0$ Hz, 1H), 3.64 (t, $J = 8.0$ Hz, 1H), 3.33 (dd, $J = 12.0, 4.0$ Hz, 1H), 2.94-3.09 (m, 1H), 2.82-2.88 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 162.79 (t), 140.79, 136.59, 129.07, 128.70, 127.27, 126.37 (q), 116.96 (t, $J = 244$ Hz), 47.88, 41.30 (t, $J = 21$ Hz), 31.36; ^{19}F NMR (376 MHz, CDCl_3) δ : -62.46, -109.87 (d, $J = 266.96$ Hz), -117.29 (d, $J = 266.96$ Hz); HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{15}\text{F}_3\text{NO}$ $[\text{M}+\text{H}]^+$: 356.1068, found: 356.1065.

1-(4-acetylphenyl)-4-benzyl-3,3-difluoropyrrolidin-2-one(3ah)

white solid; ^1H NMR (400 MHz, CDCl_3) δ : 7.98 (d, $J = 8.0$ Hz, 2H), 7.75 (d, $J = 8.0$ Hz, 2H), 7.38 (t, $J = 8.0$ Hz, 2H), 7.27-7.33 (m, 3H), 3.79 (t, $J = 8.0$ Hz, 1H), 3.65 (t, $J = 8.0$ Hz, 1H), 3.32 (dd, $J = 12.0, 4.0$ Hz, 1H), 2.92-3.03 (m, 1H), 2.81-2.87 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 196.80, 163.11 (t), 141.75, 141.76, 136.61, 134.26, 129.52, 129.07, 128.71, 127.25, 119.12, 117.04 (t, $J = 249$ Hz), 47.86, 41.26 (t, $J = 21$ Hz), 31.37, 26.55; ^{19}F NMR (376 MHz, CDCl_3) δ : -109.82 (d, $J = 266.96$ Hz), -117.17 (d, $J = 266.96$ Hz); HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{18}\text{F}_2\text{NO}_2$ $[\text{M}+\text{H}]^+$: 330.1300, found: 330.1308.

4-benzyl-3,3-difluoro-1-(3-fluoro-4-methylphenyl)pyrrolidin-2-one(3ai)

white solid; ^1H NMR (400 MHz, CDCl_3) δ : 7.17-7.46 (m,

8H), 3.71 (t, $J = 8.0$ Hz, 1H), 3.57 (t, $J = 8.0$ Hz, 1H), 3.30 (dd, $J = 12.0, 4.0$ Hz, 1H), 2.91-2.99 (m, 1H), 2.79-2.85 (m, 1H), 2.28 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 162.79 (t), 162.24 (d, $J = 243$ Hz), 136.93, 131.62, 129.03, 128.71, 127.19, 122.81, 117.25 (t, $J = 248$ Hz), 114.82, 107.36, 107.07, 48.08, 41.31 (t, $J = 21$ Hz), 31.45, 14.19; ^{19}F NMR (376 MHz, CDCl_3) δ : -111.15 (d, $J = 266.96$ Hz), -115.99, -118.66 (d, $J = 266.96$ Hz); HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{17}\text{F}_3\text{NO}$ $[\text{M}+\text{H}]^+$: 320.1257, found: 320.1253.

4-benzyl-1-(4-chloro-3-methoxyphenyl)-3,3-difluoropyrrolidin-2-one(3aj) white solid; ^1H NMR (400 MHz, CDCl_3) δ : 7.74 (s, 1H), 7.27-7.33 (m, 6H), 6.78 (d, $J = 8.0$ Hz, 1H), 3.93 (s, 3H), 3.74 (t, $J = 8.0$ Hz, 1H), 3.59 (t, $J = 8.0$ Hz, 1H), 3.32 (dd, $J = 16.0, 4.0$ Hz, 1H), 2.91-2.98 (m, 1H), 2.80-2.86 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 162.55 (t), 155.30, 137.63, 136.69, 130.06, 129.05, 128.71, 127.22, 119.82, 117.29 (t, $J = 236$ Hz), 111.36, 104.81, 56.30, 48.19, 41.27 (t, $J = 21$ Hz), 31.44; ^{19}F NMR (376 MHz, CDCl_3) δ : -109.48 (d, $J = 266.96$ Hz), -117.48 (d, $J = 266.96$ Hz); HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{17}\text{ClF}_2\text{NO}_2$ $[\text{M}+\text{H}]^+$: 352.0910, found: 352.0913.

Acknowledgements

This work was supported by National Natural Science Foundation of China (21572046). Financial support from the Program of “543 team” of Henan University of Engineering and the Youth Doctoral Funding of Henan University of Engineering (2015017) is gratefully acknowledged.

Notes and references

- (a) K. Müller, C. Faeh, F. Diederich, *Science*, 2007, **317**, 1881; (b) S. Purser, P. R. Moore, S. Swallow, V. Gouverneur, *Chem. Soc. Rev.* 2008, **37**, 320.
- (a) T. Furuya, A. S. Kamlet, T. Ritter, *Nature*, 2011, **473**, 470; (b) O. A. Tomashenko, V. V. Grushin, *Chem. Rev.* 2011, **111**, 4475; (c) T. Chatterjee, N. Iqbal, Y. You, E. J. Cho, *Acc. Chem. Res.* 2016, **49**, 2284; (d) S. L. Shi, S. L. Buchwald, *Angew. Chem., Int. Ed.* 2015, **54**, 1646; (e) P. Novák, A. Lishchynskiy, V. V. Grushin, *J. Am. Chem. Soc.* 2012, **134**, 16167; (f) P. S. Fier, J. F. Hartwig, *Science*, 2013, **342**, 956; (g) W. Liu, X. Huang, M.-J. Cheng, R. J. Nielsen, W. A. Goddard III, J. T. Groves, *Science*, 2012, **337**, 1322; (h) E. J. Cho, T. D. Senecal, T. Kinzel, Y. Zhang, D. A. Watson, S. L. Buchwald, *Science*, 2010, **328**, 1679; (i) Y. Zeng, C. Ni, J. Hu, *Chem. Eur. J.* 2016, **22**, 3210; (j) Z. Li, L. Song, C. Li, *J. Am. Chem. Soc.* 2013, **135**, 4640; (k) Z. Li, Z. Wang, L. Zhu, X. Tan, C. Li, *J. Am. Chem. Soc.* 2014, **136**, 16439; (l) F. Yin, Z. Wang, Z. Li, C. Li, *J. Am. Chem. Soc.* 2012, **134**, 10401; (m) Y. Ye, M. S. Sanford, *J. Am. Chem. Soc.* 2013, **135**, 4648.
- (a) C. Han, A. E. Salyer, E. H. Kim, X. Jiang, R. E. Jarrard, M. S. Powers, A. M. Kirchhoff, T. K. Salvador, J. A. Chester, G. H. Hockerman, D. A. Colby, *J. Med. Chem.* 2013, **56**, 2456; (b) J. Li, S. Y. Chen, B. J. Murphy, N. Flynn, R. Seethala, D. Slusarchyk, M. Yan, P. Sleph, H. Zhang, W. G. Humphreys, W. R. Ewing, J. A. Robl, D. Gordon, J. A. Tino, *Bioorg. Med. Chem. Lett.* 2008, **18**, 4072.
- (a) S. Larsson, N. Rønsted, *Curr. Top. Med. Chem.* 2014, **14**, 274; (b) A. K. Mailyan, J. A. Eickhoff, A. S. Minakova, Z. Gu, P. Lu, A. Zakarian, *Chem. Rev.* 2016, **116**, 4441.
- (a) T. Sifferlen, A. Boller, A. Chardonneau, E. Cottreel, J. Gatfield, A. Treiber, C. Roch, F. Jenck, H. Aissaoui, J. T. Williams, C. Brotschi, B. Heidmann, R. Siegrist, C. Boss, *Bioorg. Med. Chem. Lett.* 2015, **25**, 1884. (b) H. Nagashima, Y. Isono, S.-i. Iwamatsu, *J. Org. Chem.* 2001, **66**, 315; (c) S. Fustero, B. Fernández, P. Bello, C. del Pozo, S. Arimitsu, G. B. Hammond, *Org. Lett.* 2007, **9**, 4251; (d) Z. Zhang, X. Tang, C. S. Thomason, W. R. Dolbier, *Org. Lett.* 2015, **17**, 3528.
- B.-H. Li, K.-L. Li, Q.-Y. Chen, *J. Fluorine Chem.* 2012, **133**, 163.
- (a) M. Zhang, W. Li, Y. Duan, P. Xu, S. Zhang, C. Zhu, *Org. Lett.* 2016, **18**, 3266; (b) Y. Lv, W. Pu, Q. Wang, Q. Chen, J. Niu, Q. Zhang, *Adv. Synth. Catal.* 2017, **359**, 3114.
- H. Chen, X. Wang, M. Guo, W. Zhao, X. Tang, G. G. Wang, *Org. Chem. Front.* 2017, **4**, 2403.
- (a) W.-P. Mai, J.-T. Wang, L.-R. Yang, J.-W. Yuan, Y.-M. Xiao, P. Mao, L.-B. Qu, *Org. Lett.* 2014, **16**, 204; (b) W.-P. Mai, G.-C. Sun, J.-T. Wang, G. Song, P. Mao, L.-R. Yang, J.-W. Yuan, Y.-M. Xiao, L.-B. Qu, *J. Org. Chem.* 2014, **79**, 8094; (c) W.-P. Mai, B. Sun, G.-S. Qian, J.-W. Yuan, P. Mao, L.-R. Yang, Y.-M. Xiao, *Tetrahedron*, 2015, **71**, 8416; (d) W.-P. Mai, J.-T. Wang, Y.-M. Xiao, P. Mao, K. Lu, *Tetrahedron*, 2015, **71**, 8041; (e) J.-W. Yuan, S.-N. Liu, W.-P. Mai, *Org. Biomol. Chem.* 2017, **15**, 7654.
- (a) A. Tarui, S. Shinohara, K. Sato, M. Omote, A. Ando, *Org. Lett.* 2016, **18**, 1128; (b) J. W. Gu, Q.-Q. Min, L. C. Yu, X. Zhang, *Angew. Chem. Int. Ed.* 2016, **55**, 12270; (c) Z. Feng, Q.-Q. Min, Y.-L. Xiao, B. Zhang, X. Zhang, *Angew. Chem. Int. Ed.* 2014, **53**, 1669; (d) Y.-L. Xiao, W.-H. Guo, G.-Z. He, Q. Pan, X. Zhang, *Angew. Chem. Int. Ed.* 2014, **53**, 9909; (e) Z. Feng, Q.-Q. Min, X.-P. Fu, L. An, X. Zhang, *Nature Chem.* 2017, **9**, 918; (f) H.-Y. Zhao, F. Zhang, Z. Luo, X. Zhang, *Angew. Chem. Int. Ed.* 2016, **55**, 10401; (g) Y.-L. Xiao, Q.-Q. Min, C. Xu, R.-W. Wang, X. Zhang, *Angew. Chem. Int. Ed.* 2016, **55**, 5873; (h) Y.-M. Su, Y. Hou, F. Yin, Y.-M. Xu, Y. Li, X. Zheng, X.-S. Wang, *Org. Lett.* 2014, **16**, 2958; (i) J. Sheng, H.-Q. Ni, G. Liu, Y. Li, X.-S. Wang, *Org. Lett.* 2017, **19**, 4480; (j) G. Li, T. Wang, F. Fei, Y.-M. Su, Y. Li, Q. Lan, X.-S. Wang, *Angew. Chem. Int. Ed.* 2016, **55**, 3491.
- J. Yamaguchi, K. Muto, K. Itami, *Eur. J. Org. Chem.* 2013, **2013**, 19.
- (a) J. Wang, T. Qin, T.-G. Chen, L. Wimmer, J. T. Edwards, J. Cornella, B. Vokits, S. A. Shaw, P. S. Baran, *Angew. Chem. Int. Ed.* 2016, **55**, 9676; (b) S. Rezazadeh, V. Devannah, D. A. Watson, *J. Am. Chem. Soc.* 2017, **139**, 8110; (c) H. Yue, C. Zhu, M. Rueping, *Angew. Chem. Int. Ed.* 2018, **57**, 1371; (d) A. Chatupheeraphat, H.-H. Liao, W. Srimontree, L. Guo, Y. Minenkov, A. Poater, L. Cavallo, M. Rueping, *J. Am. Chem. Soc.* 2018, **140**, 3724; (e) W. Srimontree, A. Chatupheeraphat, H.-H. Liao, M. Rueping, *Org. Lett.* 2017, **19**, 3091; (f) K. M. Cobb, J. M. Rabb-Lynch, E. H. Hoerrner, A. Manders, Q. Zhou, M. P. Watson, *Org. Lett.* 2017, **19**, 4355; (g) C. H. Basch, K. M. Cobb, M. P. Watson, *Org. Lett.* 2016, **18**, 136; (h) Q. Zhou, K. M. Cobb, T. Tan, M. P. Watson, *J. Am. Chem. Soc.* 2016, **138**, 12057; (i) A. G. Domínguez, S. Mgller, C. Nevado, *Angew. Chem. Int. Ed.* 2017, **56**, 9949; (j) Z. Li, A. G. Domínguez, C. Nevado, *Angew. Chem. Int. Ed.* 2016, **55**, 6938.